News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

U3 Pharma Appoints Dr Joanna Horobin As Chief Executive Officer



10/19/2005 5:09:32 PM

MARTINSRIED, Germany, July 12 /PRNewswire/ -- U3 Pharma AG, an oncology company developing therapeutic antibodies directed against novel targets in cell signaling pathways, announced today the appointment of Dr. Joanna Horobin as CEO. Dr. Horobin joins U3 Pharma with an impressive track record garnered in pharmaceutical and biotechnology companies.

"Joanna has an extensive background in launching innovative and commercially successful oncology products, including Taxotere and Campto. Her clinical and R&D experience combined with her savvy marketing expertise places her in an excellent position to drive the future development of U3 Pharma and its products," stated Prof. Axel Ullrich, founder of U3 Pharma. "We believe that Joanna is ideal to lead the company and joins us at a pivotal time as we move forward both in terms of corporate development and in meeting key objectives for our novel cancer therapeutics."

Dr. Horobin stated, "This is an exciting time to join U3 Pharma. The company is advancing the next generation of anticancer products based on pioneering cell signaling research by Prof. Ullrich. His original work has resulted in the first oncoprotein-targeted cancer therapeutic Herceptin and the multi-targeted small molecule drug SUTENT (SU11248). I look forward to leading the company that will build on this success."

Dr. Horobin joins U3 Pharma from MPM Capital where she was Entrepreneur-in-Residence. Prior to MPM Capital, Dr. Horobin was Chief Operating Officer at CombinatoRx where she secured $70 million in venture financing facilitating the transition of that company from a research to a development stage enterprise with multiple clinical programs. Before CombinatoRx, Dr. Horobin was Executive Vice President, Commercial Development at EntreMed. In this role, Dr. Horobin played a major role in securing over $80 million of financing. She was also instrumental in initiating clinical development of three angiogenesis inhibitors, Panzem, Endostatin and Angiostatin.

In her earlier pharmaceutical career Dr Horobin was responsible for the approval and commercial launch of multiple new drugs. Dr. Horobin spent eight years at Rhone-Poulenc Rorer and its subsidiaries and pre-merger companies, holding several clinical and senior management positions. From 1994 -1998, Dr. Horobin was Vice President, Oncology and launched Rhone-Poulenc Rorer as a global player in oncology, driven by the successful introduction of Taxotere and Campto. Before moving to the US, Dr. Horobin was General Manager of Chugai Rhone-Poulenc in Paris, where she directed the successful joint venture between the two companies. In this position, she oversaw the development and commercial launch of the G-CSF product Granocyte, the first CPMP approval for a biotech product. Prior to this, Dr. Horobin was Medical Director of RPR UK and Rorer Health Care.

Dr. Horobin started her pharmaceutical career at Beecham Pharmaceuticals as a medical advisor and culminating in the position of Head of Clinical Investigation. This followed four years in clinical practice in the UK. Dr. Horobin gained her medical degree at the University of Manchester, is a Member of the Royal College of General Practitioners and also holds a Diploma in Pharmaceutical Medicine from the Royal College of Physicians. Dr. Horobin also currently serves as President, Boston Chapter of the Healthcare Businesswomen's Association.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

About U3 Pharma

U3 Pharma AG is a biopharmaceutical company focused on the creation of novel therapeutic products that specifically target key components of cellular signal transduction systems that are involved in major important human diseases such as cancer. The company has licensed a portfolio of validated drug targets from the Max Planck Society based on pioneering research by Prof. Axel Ullrich. These drug targets have been used to discover a portfolio of therapeutic antibodies that U3 Pharma is advancing towards clinical development. The company has signed drug discovery and development collaborations with Abgenix, Fremont, California, for therapeutic antibodies and Evotec, Hamburg, Germany, for small molecule drugs. U3 Pharma is privately held and based in Martinsried, Munich, Germany.

For additional information, visit www.u3pharma.com.

U3 Pharma AG

CONTACT: Contacts: U3 Pharma, Joanna Horobin, +49-(0)89-8103-9111,jhorobin@u3pharma.com; Halsin Partners, Mike Sinclair, +44-(0)870-747-0880,msinclair@halsin.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES